# Peptide Stacks: 6 Combos and the HHS Blend Rule

**By telos rx Editorial Team** · 2026-11-18

**Peptide stacks are combinations of two or more peptides, often sold in one vial. Most have little or no combined human data, and pre-mixed blends fall outside the HHS compounding policy. Here is what that means, and what [telos rx](https://telosrx.com/pages/bpc-157-tb500) offers instead.**

_Written by the telos rx Editorial Team. Last reviewed: 18 November 2026._

How we built this guide

-   **What we compared:** six peptide stacks people often ask about, and how each fits the October 2026 HHS interim enforcement discretion policy.
-   **How:** we read the Federal Register notice, PubMed-indexed reviews and the one controlled animal study we found that tested a stack against its parts.
-   **Who:** the telos rx Editorial Team.
-   **Date checked:** 18 November 2026.
-   **What this is not:** a ranking or a protocol. No stack below is a plan to follow.

Search for peptide stacks and you will find recovery stacks, longevity stacks and focus stacks. Many come pre-mixed in a single vial with a catchy name.

The idea is that two peptides work better together. The evidence for that idea is very thin. And in the US, a blended vial now sits outside the federal compounding policy that covers several of these peptides.

## What is a peptide stack?

A stack is any plan that uses two or more peptides over the same period. Sometimes they are given as separate products. Often, online sellers mix them into one vial.

Those are very different things. Separate products let a prescriber adjust or stop each one. A blend locks the ratio and makes it hard to tell which peptide caused a side effect.

## Why blends fall outside the HHS policy

On 30 October 2026, HHS published an [interim enforcement discretion policy in the Federal Register](https://www.federalregister.gov/d/2026-22192), document 2026-22192. It covers six peptides: BPC-157, TB-500, MOTS-c, epitalon, Semax and KPV.

HHS said it will not take enforcement action against state-licensed pharmacies and physicians compounding these peptides until each is addressed in a final rule. The conditions include:

-   **Single active ingredient:** each compounded product may contain only one listed peptide. No blends.
-   **Prescription:** a valid, patient-specific prescription.
-   **Suppliers:** ingredients from FDA-registered facilities with a valid certificate of analysis.
-   **Routes:** each peptide is limited to certain routes. For example, Semax is intranasal only, and KPV is topical or oral only.

This is not FDA approval. It is not a final listing, and HHS can revise it. Our [HHS peptide policy explainer](https://telosrx.com/blogs/peptides/hhs-peptide-enforcement-policy-explained) covers every condition. This summary reflects the policy as checked on 18 November 2026.

## 6 peptide stacks people ask about

Here are the stacks that come up most in searches and forums. For each one, we note the evidence type and how it fits the HHS policy.

### 1\. BPC-157 and TB-500, the recovery stack

**Evidence:** animal only for the combination. A 2026 [rat study of Achilles tendon repair](https://pubmed.ncbi.nlm.nih.gov/42542926/) tested each peptide alone and together. The combination did not add any benefit over either peptide alone.

**HHS policy:** both peptides are covered, but a single blended vial is not. A provider may prescribe each as its own single-ingredient product.

telos rx offers this pair only as two separate single-ingredient vials, never one blend. Compounded BPC-157 and TB-500 are not FDA-approved.

_telos rx publishes this guide and is one of the options listed._

### 2\. Epitalon and MOTS-c, the longevity stack

**Evidence:** no published human study has tested these two together. Each has mostly animal and cell research behind it.

**HHS policy:** both are covered as single-ingredient products. Epitalon is covered for subcutaneous or intramuscular use in intermittent courses. MOTS-c is covered for subcutaneous or intramuscular use. A blend is outside the policy.

### 3\. BPC-157 and KPV, the gut stack

**Evidence:** no human study of the pair that we found. KPV research is mainly in cells and animal models of gut inflammation.

**HHS policy:** both are covered as separate products. KPV is limited to topical and oral use. A combined product is outside the policy.

### 4\. Semax and Selank, the focus stack

**Evidence:** both were developed in Russia, and most studies come from there. No controlled US trial has tested the pair.

**HHS policy:** Semax is covered for intranasal use only, as a single ingredient. Selank is not covered by the policy at all.

### 5\. CJC-1295 and ipamorelin

**Evidence:** this pair is marketed for growth hormone release. Rigorous human safety data for this use are scarce.

**HHS policy:** neither peptide is among the six covered by the October 2026 policy.

### 6\. MOTS-c with a GLP-1 medication

**Evidence:** no published human study of this pairing that we found. GLP-1 medications have large trials of their own. MOTS-c does not.

**HHS policy:** MOTS-c is covered as a single ingredient. GLP-1 medications are outside this peptide policy, and any combined product would not meet its single-ingredient condition.

Want a provider to review peptide options?

telos rx offers BPC-157 and TB-500 only as two separate single-ingredient vials, never a blend. Both are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.

[See the two-vial option](https://telosrx.com/pages/bpc-157-tb500)

## Peptide stacks at a glance

| Stack | Combined human data | Covered by HHS policy as a blend? |
| --- | --- | --- |
| BPC-157 and TB-500 | None | No  |
| Epitalon and MOTS-c | None | No  |
| BPC-157 and KPV | None | No  |
| Semax and Selank | None from controlled US trials | No, and Selank is not covered |
| CJC-1295 and ipamorelin | Scarce | No, neither is covered |
| MOTS-c and a GLP-1 | None | No  |

## Do peptide stacks work better?

There is little evidence either way. Stacking is mostly a marketing idea built on animal studies of single peptides.

**Animal evidence:** the one controlled stack study we found, in rats, showed no added benefit from combining BPC-157 and TB-500.

**Human evidence:** we found no controlled human trial of any popular peptide stack. A 2026 [review in _Sports Medicine_](https://pubmed.ncbi.nlm.nih.gov/41966639/) found rigorous human safety data scarce even for single gray-market peptides.

## Safety concerns with stacking

-   **Unknown interactions:** no one has studied how most of these peptides behave together in people.
-   **Harder to trace side effects:** with a blend, you cannot tell which peptide caused a reaction.
-   **Fixed ratios:** a blend cannot be adjusted one peptide at a time.
-   **Quality:** blends sold for research use only may not contain what the label says.
-   **Cancer history:** several of these peptides are studied for blood vessel growth. There is no human data on what that means for people with cancer.

Contact your clinician about any new or worrying symptom. Seek urgent care for swelling of the face or throat, or trouble breathing.

## Stacks and sport testing

BPC-157 and TB-500 fall under category S0, non-approved substances, on the WADA Prohibited List. MOTS-c is named under S4, hormone and metabolic modulators. If you compete in tested sport, check the current list before using any peptide.

## Stacks vs standard care

Most people look at stacks for recovery, energy or focus. For those goals, the basics have stronger evidence: medical evaluation, physical therapy, sleep, nutrition and regular training.

A stack does not replace any of these. Our [review of recovery peptide research](https://telosrx.com/blogs/peptides/best-peptides-for-recovery-research-review) compares the options fairly.

## Questions to ask before any peptide combination

-   What evidence supports each peptide for my situation?
-   Is each product a single active ingredient from a state-licensed pharmacy?
-   How will we tell which peptide caused a side effect?
-   When would we stop one or both?
-   What does each cost, given how thin the evidence is?

Read our guides to [BPC-157 vs TB-500](https://telosrx.com/blogs/peptides/bpc-157-vs-tb-500) and [what BPC-157 is](https://telosrx.com/blogs/peptides/what-is-bpc-157) for more detail.

## How telos rx approaches peptide combinations

telos rx is an online-first, asynchronous telehealth service. You complete a private intake online, on your schedule. A licensed provider reviews it and decides whether any peptide fits.

TB-500 is not sold on its own. It is offered only with BPC-157, as two separate single-ingredient vials. The provider determines the dose and schedule for each vial, and medication ships ready to inject. The [BPC-157 and TB-500 page](https://telosrx.com/pages/bpc-157-tb500) lists it as low as $133 per month, as of 18 November 2026.

## The bottom line

Peptide stacks are popular, but combined human evidence is close to zero. Pre-mixed blends fall outside the HHS single-ingredient condition. If a combination is considered at all, separate products prescribed by a licensed provider are the safer structure.

_Change log: published 18 November 2026._

Start a private peptide evaluation

Answer health questions online, on your schedule. A licensed provider reviews them, and any prescription is subject to medical approval by a licensed provider.

[Check my eligibility](https://telosrx.com/pages/bpc-157-tb500)

## Frequently Asked Questions

### What is a peptide stack?

A peptide stack is a plan that uses two or more peptides over the same period. Some are given as separate products, and many online sellers mix them into one vial. Very few stacks have been tested together in people, so most claims about stacks rest on animal studies of single peptides.

### Why are peptide blends outside the HHS policy?

The October 2026 HHS interim enforcement discretion policy requires each compounded product to contain a single listed active ingredient. A pre-mixed vial with two peptides does not meet that condition. The policy also requires a patient-specific prescription and FDA-registered ingredient suppliers, and it can be revised.

### Is the BPC-157 and TB-500 stack effective?

There is no human trial of the combination. One small rat study of Achilles tendon repair found that combining them did not add benefit over either peptide alone. Both peptides are not FDA-approved. A licensed provider can weigh the limited evidence and standard care options with you.

### Can a provider prescribe two peptides at once?

A provider may prescribe more than one peptide as separate single-ingredient products if they judge it appropriate. That is a clinical decision based on your history and the evidence. telos rx offers BPC-157 and TB-500 only as two separate vials, and any prescription is subject to medical approval by a licensed provider.

### Is Selank covered by the HHS peptide policy?

No. The October 2026 policy covers BPC-157, TB-500, MOTS-c, epitalon, Semax and KPV. Selank is not covered. Semax is covered for intranasal use only, as a single ingredient, so a Semax and Selank blend falls outside the policy. telos rx does not offer Selank.

### Are peptide stacks allowed in tested sport?

Many are not. BPC-157 and TB-500 fall under category S0 on the WADA Prohibited List, and MOTS-c is named under S4. A prescription does not change anti-doping status. If you compete in a tested sport, check the current list and your sport's rules first.

_telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service._

Ready to see if it fits? [Start your private evaluation with telos rx](https://telosrx.com/pages/bpc-157-tb500).

**Tags:** BPC-157, cc-160, content-calendar, HHS policy, peptide research, peptide stacks, plan-2027, TB-500

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/peptide-stacks-and-hhs-blend-rule)
